Get startedLog in
    Picture of HUTCHMED (China) logo

    13 — HUTCHMED (China) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Hutchmed (China) Gets NMPA Conditional Approval For Tazverik® (Tazemetostat)

    Picture of HUTCHMED (China) logoHUTCHMED (China)
    21/03/2025 12:00
    March 21 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

NMPA CONDITIONAL APPROVAL FOR TAZVERIK® (TAZEMETOSTAT) FOR TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on HUTCHMED (China)

    See all news